Citations

Mayo Clinic

Showing 10 of 108522 citations.

Angiosarcoma of the Scalp and Face
Patel, Samir H. , Hayden, Richard E. , Hinni, Michael L., Wong, William W. , Foote, Robert L. , Milani, Shadi, Halyard, Michele Y. , Ko, Stephen J. , Wu, Qing Feng

JAMA Otolaryngology–Head & Neck Surgery | January 29, 2015 | Volume: 141 | Issue: 4 | Pages: 335

10.1001/jamaoto.2014.3584 | PMID 25634014 Get It

Blind men and an elephant
Kumar, Shaji

Blood | January 29, 2015 | Volume: 125 | Issue: 5 | Pages: 745-747

10.1182/blood-2014-12-615328 | PMID 25634613 Get It

Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease
Lindor, Keith D. , Tabibian, James H.

Alimentary Pharmacology & Therapeutics | January 29, 2015 | Volume: 41 | Issue: 5 | Pages: 490-490

10.1111/apt.13068 | PMID 25631651 Get It

Minimally Disruptive Medicine: A Pragmatically Comprehensive Model for Delivering Care to Patients with Multiple Chronic Conditions
Leppin, Aaron L. , Gionfriddo, Michael R. , Montori, Víctor M.

Healthcare | January 29, 2015 | Volume: 3 | Issue: 1 | Pages: 50-63

10.3390/healthcare3010050 | PMID 27417747 Get It

An increasing proportion of healthcare resources in the United States are directed toward an expanding group of complex and multimorbid patients. Federal stakeholders have called for new models of care to meet the needs of these patients. Minimally Disruptive Medicine (MDM) is a theory-based, patient-centered, and context-sensitive approach to care that focuses on achieving patient goals for life and health while imposing the smallest possible treatment burden on patients’ lives. The MDM Care Model is designed to be pragmatically comprehensive, meaning that it aims to address any and all factors that impact the implementation and effectiveness of care for patients with multiple chronic conditions. It comprises core activities that map to an underlying and testable theoretical framework. This encourages refinement and future study. Here, we present the conceptual rationale for and a practical approach to minimally disruptive care for patients with multiple chronic conditions. We introduce some of the specific tools and strategies that can be used to identify the right care for these patients and to put it into practice.
Reevaluation of Commercial Reagents for Detection of Histoplasma capsulatum Antigen in Urine
Theel, Elitza S. , Harring, Julie, Dababneh, Ala S. , Rollins, Leonard O., Bestrom, Jeannie E., Jespersen, Deborah J., Harring, Julie A, Bestrom, Jean E.

Journal of Clinical Microbiology | January 29, 2015 | Volume: 53 | Issue: 4 | Pages: 1198-1203

10.1128/jcm.03175-14 | PMID 25631806 Get It

ABSTRACT Detection of the Histoplasma capsulatum urinary antigen (UAg) is among the most sensitive and rapid means to diagnose histoplasmosis. Previously, we evaluated analyte-specific reagents (ASR) manufactured by IMMY (Norman, OK) for detection of Histoplasma galactomannan (GM) in urine using an enzyme immunoassay (EIA), and we showed low positive agreement (64.5%) with the MiraVista (MVista) Histoplasma antigen (Ag) quantitative EIA (MiraVista Diagnostics, Indianapolis, IN). Here we reevaluated the IMMY GM ASR following modification of our original assay protocol and introduction of an indeterminate range. A total of 150 prospectively collected urine samples were tested with both the IMMY and MVista EIAs, and clinical histories were recorded for all study subjects. The IMMY GM ASR showed positive and negative agreements of 82.3% (14/17 samples) and 100% (121/121 samples), respectively (with exclusion of 12 indeterminate results), and overall agreement of 90% (135/150 samples) with respect to the MVista EIA. Of the three patients with negative IMMY GM ASR results and positive MVista EIA results, testing was performed for initial diagnostic purposes for one patient (<0.4 ng/ml by the MVista EIA) and UAg levels were being monitored for the remaining two patients (both <0.7 ng/ml by the MVista EIA). The MVista EIA results were positive for 6/12 samples that tested indeterminate by the IMMY GM ASR. We also show that the IMMY GM ASR can be used to serially monitor Histoplasma UAg levels. In conclusion, we demonstrate that, with modification, the IMMY GM ASR is a reliable rapid assay for detection of Histoplasma UAg.
Smoking and white matter hyperintensity progression
Sharrett, A. Richey , Jack, Clifford R. , Power, Melinda C. , Deal, Jennifer A. , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F. , Jack, Clifford R

Neurology | January 28, 2015 | Volume: 84 | Issue: 8 | Pages: 841-848

10.1212/wnl.0000000000001283 | PMID 25632094 Get It

Androgens regulate SMAD ubiquitination regulatory factor‐1 expression and prostate cancer cell invasion
Gang, Xiaokun , Wang, Guixia , Huang, Haojie

The Prostate | January 28, 2015 | Volume: 75 | Issue: 6 | Pages: 561-572

10.1002/pros.22935 | PMID 25631036 Get It

BACKGROUNDProstate cancer (PCa) is the most commonly diagnosed male cancer in the United States and is a hormone‐driven disease. Androgens have been recognized as a major promoter of PCa development and progression. However, the mechanism of androgen action in PCa, especially in PCa cell invasion and metastasis remains largely unclear. SMAD ubiquitination regulatory factor‐1 (SMURF1) is a C2‐WW‐HECT‐domain E3 ubiquitin ligase that plays important roles in cancer cell metastasis. Whether there is a relationship between androgens and SMURF1 expression is not known.METHODSThe effect of androgens on the expression of SMURF1 in PCa cell lines was examined by Western blot analyses and reverse transcription‐polymerase chain reaction (RT‐PCR). Gene transfection was performed by electroporation to manipulate the expression levels of proteins studied. The binding of AR to the SMURF1 gene enhancer was determined by chromatin immunoprecipitation (ChIP) assay. Cell migration and invasion was measured by wound healing and Matrigel invasion assays, respectively.RESULTSWe found that expression of SMURF1 is upregulated by androgens in PCa cell lines and that this effect of androgens is mediated through the androgen receptor (AR). We further showed that androgens regulate SMURF1 expression at transcriptional level and provided evidence that AR transcriptionally activates SMURF1 by binding to its enhancer that contains a canonical half androgen responsive element (ARE). Finally, we demonstrated that SMURF1 is important for androgen‐induced invasion of PCa cells.CONCLUSIONSWe demonstrate for the first time that SMURF1 is a bona fide target gene of the AR. Our findings also suggest a potential role of SMURF1 in PCa metastasis. Prostate 75: 561–572, 2015. © 2015 Wiley Periodicals, Inc.
Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center
Franco, Diana L. , Disbrow, Molly, Koepke, Laura, Harris, Lucinda A. , Harrison, M. Edwyn , Ramirez, Francisco C. , Disbrow, Molly B, Kahn, Allon , Koepke, Laura M, Harrison, M Edwyn , Crowell, Michael D , Crowell, Michael D.

Gastroenterology Research and Practice | January 28, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-5

10.1155/2015/971582 | PMID 25694782 Get It

Duodenal aspirates are not commonly collected, but they can be easily used in detection of small intestinal bacterial overgrowth (SIBO). Proton pump inhibitor (PPI) use has been proposed to contribute to the development of SIBO. We aimed to determine the yield of SIBO-positive cultures detected in duodenal aspirates, the relationship between SIBO and PPI use, and the clinical outcomes of patients identified by this method. In a retrospective study, we analyzed electronic medical records from 1263 consecutive patients undergoing upper endoscopy at a tertiary medical center. Aspirates were collected thought out the third and fourth portions of the duodenum, and cultures were considered to be positive for SIBO if they produced more than 100,000 cfu/mL. Culture analysis of duodenal aspirates identified SIBO in one-third of patients. A significantly higher percentage of patients with SIBO use PPIs than patients without SIBO, indicating a possible association. Similar proportions of patients with SIBO improved whether or not they received antibiotic treatment, calling into question the use of this expensive therapy for this disorder.
Collagen gel contraction as a measure of fibroblast function in an animal model of subsynovial connective tissue fibrosis
Yang, Tai‐Hua , Thoreson, Andrew R. , Gingery, Anne , Passe, Sandra, An, Kai‐Nan, Zhao, Chunfeng , Amadio, Peter C. , Larson, Dirk R. , An, Kai‐Nan , Gingery, Anne

Journal of Orthopaedic Research | January 28, 2015 | Volume: 33 | Issue: 5 | Pages: 668-674

10.1002/jor.22835 | PMID 25626430 Get It

ABSTRACTCarpal tunnel syndrome (CTS) is a peripheral neuropathy characterized by non‐inflammatory fibrosis of the subsynovial connective tissues (SSCT). A rabbit model of CTS was developed to test the hypothesis that SSCT fibrosis causes the neuropathy. We used a cell‐seeded collagen‐gel contraction model to characterize the fibrosis in this model in terms of cellular mechanics, specifically to compare the ability of SSCT cells from the rabbit model and normal rabbits to contract the gel, and to assess the effect of transforming growth factor‐β1,which is upregulated in CTS, on these cells. SSCT fibrosis was induced in six retired breeder female rabbits which were sacrificed at 6 weeks (N = 3) and 12 weeks (n = 3). An additional two rabbits served as controls. SSCT was harvested according to a standard protocol. Gels seeded with SSCT cells from rabbits sacrificed at 6 weeks had significantly higher tensile strength (p < 0.001) and Young's modulus (p < 0.001) than gels seeded with cells from rabbits sacrificed at 12 weeks or control animals. TGF‐β1 significantly increased the decay time constant (p < 0.001), tensile strength (p < 0.001), and Young's modulus (p < 0.001) regardless of the cell source. This model may be useful in screening therapeutic agents that may block SSCT fibrosis, identifying possible candidates for CTS treatment. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:668–674, 2015.